Rifampicin
- Generic Name
- Rifampicin
- Brand Names
- Isonarif, Rifadin, Rifamate, Rifater, Rofact
- Drug Type
- Small Molecule
- Chemical Formula
- C43H58N4O12
- CAS Number
- 13292-46-1
- Unique Ingredient Identifier
- VJT6J7R4TR
- Background
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericid...
- Indication
Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.
- Associated Conditions
- Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis
- Associated Therapies
- Antibacterial therapy
1HP Versus 3HR in the Treatment of Tuberculosis Infection in Vietnam
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-02-20
- Target Recruit Count
- 350
- Registration Number
- NCT06191692
- Locations
- 🇻🇳
Ha Noi Lung Hospital, Hà Nội, Vietnam
🇻🇳Vietnam National Lung Hospital, Hà Nội, Ha Noi, Vietnam
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-11-13
- Target Recruit Count
- 315
- Registration Number
- NCT06192160
- Locations
- 🇺🇬
12401, Joint Clinical Research Centre (JCRC)/Kampala CRS, Kampala, Uganda
🇲🇼30301, Blantyre CRS, Blantyre, Malawi
🇲🇼12001, Malawi CRS, Lilongwe, Malawi
A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT06162169
- Locations
- 🇨🇳
Beijing GoBroad Hospital, Beijing, Beijing, China
A Drug-drug Interaction Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Methotrexate in Elderly Subjects
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT06108453
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of
Drug-Drug Interaction (DDI) Study for TPN171H
- Conditions
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Vigonvita Life Sciences
- Target Recruit Count
- 24
- Registration Number
- NCT06090123
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China
Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-10-03
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 30
- Registration Number
- NCT06064539
- Locations
- 🇺🇸
Prism Research-Site Number:8400001, Saint Paul, Minnesota, United States
Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin
- Conditions
- Interventions
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Guangdong Raynovent Biotech Co., Ltd
- Target Recruit Count
- 56
- Registration Number
- NCT06031454
- Locations
- 🇨🇳
the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
- Conditions
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 32
- Registration Number
- NCT06004947
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM
- Conditions
- Interventions
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 1266
- Registration Number
- NCT05994742
- Locations
- 🇿🇲
UTH - University Teaching Hospital, Lusaka, Zambia
🇿🇼Chitungwiza Central Hospital, Harare, Zimbabwe
🇿🇼Sally Mugabe Hospital, Harare, Zimbabwe
Intensified Short Course Regimen for TBM in Adults
- Conditions
- Interventions
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Indian Council of Medical Research
- Target Recruit Count
- 372
- Registration Number
- NCT05917340
- Locations
- 🇮🇳
ICMR- National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.